 2008 |
|
 December 26 |
Promotion of the Program Adopted by the Special District for
Development of Advanced Medical Care (Super Special District)
- GenomIdea Conducts Evaluations for the Formulation and
Manufacture of the Active Pharmaceutical Ingredient - |
| December 10 |
Announcement of New Developments
Concerning the Manufacturing of Novel Nucleic-Acid Hybrid Decoy |
| November 17 |
The Efficacy of NF-κB/Ets Ribbon Type Decoy on
Abdominal Aortic Aneurysm Confirmed in Animal Tests
- Announcement by Osaka University at the Annual Scientific Sessions 2008
of the American Heart Association (AHA) - |
| November 12 |
Termination of Joint Development with Alfresa Pharma Corporation |
| November 12 |
New Direction in the Development of NF-κB Decoy Oligodeoxynucleotide for the Treatment of Atopic Dermatitis in Japan |
| November 4 |
Joint R&D by Three Companies into the “Drug-Eluting Balloon Catheter” to Prevent Vascular Restenosis: Efficacy Confirmed in Animal Tests - Results Announced at the 11th Annual Meeting of the Japan Society of Embolus Detection and Treatment - |
| October
28 |
Therapeutic Effects of GEN0101 on Hormone-Refractory Prostate Cancer Confirmed
- Announcement of Results of Animal Studies at the 67th Japanese Cancer Association General Meeting- |
| October
24 |
Amendments of the License Agreement between Meyer Pharmaceuticals LLC and AnGes MG, Inc. |
| October
23 |
Announcement of Results of Phase IIa Clinical Trials of STAT-1 Decoy Oligodeoxynucleotide on Psoriasis in Europe |
| October
9 |
GenomIdea, a Subsidiary of AnGes MG Enters into a Basic Agreement Toward the Signing of a Licensing Contract for GEN0101 (HVJ-E) |
| October
7 |
Letter of Intent for In-licensing of Novel DNA Vaccines for Influenza |
| October
2 |
New Medical Use Patent Granted in Europe - Covering Severe Diabetic Peripheral Artery Occlusive Diseases - |
| October
1 |
Substance Patent for a NF-κB Decoy-Oligonucleotide Granted in Japan - Covering AnGes MG’s Decoy Sequence Currently Under Development - |
| September 30 |
Announcement of Industrial/Academic Four-Party Joint R&D Project on Novel Nucleic Acid Hybrid Decoy for the Treatment of Intractable Inflammatory Diseases |
| August
6 |
A Medical Use Patent Granted in Europe for Angiogenesis Targeting a New Gene, Endothelial Nitric Oxide Synthase (eNOS) |
| July
8 |
New Medical-Use Patent for HGF Gene Therapy Granted in USA
- Covering Treatment and Prophylaxis of Auditory Dysfunction - |
| July
2 |
New Medical Use Patent for HGF Granted in Japan
- Covering the Treatment of Lymphedema - |
| May
26 |
Medical Use Patent for the Combination Use of HGF and PGIS
Granted in Europe - Covering Angiogenic Therapy - |
| May
15 |
New Medical-Use Patent for HGF Gene Granted in Europe
- Covering Cardiomyopathy - |
| April
14 |
AnGes MG, Inc. Launched Naglazyme in Japan |
| April
7 |
Medical Use Patent on NF-κB Decoy-Oligo Granted in Europe - Covering Its Use for Atopic Dermatitis |
| March
28 |
AnGes Submits NDA for HGF Gene Therapy |
| March
28 |
AnGes MG, Inc. Receives Approval for Manufacturing and Marketing of Naglazyme |
| February
25 |
Status Updates of NDA application of Naglazyme for the Treatment of Mucopolysaccharidosis VI |
| February
12 |
Supplemental Announcement of Results of Phase II Clinical Trials of NF-κB Decoy Oligodeoxinucleotides on Atopic Dermatitis |
| February
8 |
Announcement of Results of Phase II Clinical Trials of
NF-κB Decoy Oligodeoxynucleotide on Atopic Dermatitis |
